Finding Silver Linings: Incyte's Mixed Results

Incyte (NASDAQ: INCY) shareholders had a rough Thursday, with shares dropping about 10% on Thursday and another 3% Friday after ASCO abstracts were published. Jakafi, Incyte's myelofibrosis drug partnered with Johnson & Johnson, underperformed -- it failed to generate a statistically significant increase in progression-free survival or overall survival in a trial for pancreatic cancer patients.

The drug did show some clinical benefit in overall survival for a previously defined patient subgroup, with overall survival at 3 and 6 months of 48% and 42%, vs 29% and 11% for the control. Jakafi is in clinical trials for a number of other potential oncology indications -- was the drop overdone?

In this video, from Market Checkup, the Motley Fool's health care focused investing show, health care analysts Michael Douglass and David Williamson discuss the data results and key takeaways for investors.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2961425, ~/Articles/ArticleHandler.aspx, 12/20/2014 10:21:09 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement